



# The Florida Senate

## Local Funding Initiative Request

### Fiscal Year 2023-2024

LFIR # 1274

1. Project Title

Office of the State Courts Administrator (OSCA) Extended-Release Injectable Naltrexone Program

2. Senate Sponsor

Ana Maria Rodriguez

3. Date of Request

02/07/2023

4. Project/Program Description

The federal Substance Abuse and Mental Health Services Administration (SAMHSA), Food and Drug Administration (FDA) and the Centers for Disease Control (CDC) strongly advocate for the use of medication-assisted treatment as a best practice approach to serve individuals with alcohol and opioid use disorders. The requested program funds community treatment providers for provision of clinical screening, medical assessments/lab work and extended-release injectable naltrexone (Vivitrol) medication injections for individuals with alcohol and/or opioid use disorders throughout the state that are court-involved or at-risk for court involvement.

5. State Agency to receive requested funds

State Court System

State Agency contacted?

Yes

6. Amount of the Nonrecurring Request for Fiscal Year 2023-2024

Type of Funding	Amount
Operations	500,000
Fixed Capital Outlay	0
<b>Total State Funds Requested</b>	<b>500,000</b>

7. Total Project Cost for Fiscal Year 2023-2024 (including matching funds available for this project)

Type of Funding	Amount	Percentage
Total State Funds Requested (from question #6)	500,000	9%
<b>Matching Funds</b>		
Federal	0	0%
State (excluding the amount of this request)	5,000,000	91%
Local	0	0%
Other	0	0%
<b>Total Project Costs for Fiscal Year 2023-2024</b>	<b>5,500,000</b>	<b>100%</b>

8. Has this project previously received state funding?

Yes

Fiscal Year (yyyy-yy)	Amount		Specific Appropriation #	Vetoed
	Recurring	Nonrecurring		
2022-23	5,000,000	500,000	3243	No

9. Is future funding likely to be requested?

Yes

a. If yes, indicate nonrecurring amount per year.

500,000

b. Describe the source of funding that can be used in lieu of state funding.

There are minimal alternative funding sources available to this population for medication-assisted treatment (MAT) services. Medicaid, Medicare, and insurance provide very minimal and insufficient funding to provide MAT services to the target population.



# The Florida Senate

## Local Funding Initiative Request

### Fiscal Year 2023-2024

LFIR # 1274

10. Has the entity requesting this project received any federal assistance related to the COVID-19 pandemic?

No

If yes, indicate the amount of funds received and what the funds were used for.

## Complete questions 11 and 12 for Fixed Capital Outlay Projects

### 11. Status of Construction

a. What is the current phase of the project?

☐ Planning ☐ Design ☐ Construction

b. Is the project "shovel ready" (i.e. permitted)?

c. What is the estimated start date of construction?

d. What is the estimated completion date of construction?

12. List the owners of the facility to receive, directly or indirectly, any fixed capital outlay funding. Include the relationship between the owners of the facility and the entity.

### 13. Details on how the requested state funds will be expended

Spending Category	Description	Amount
<b>Administrative Costs:</b>		
Executive Director/Project Head Salary and Benefits		0
Other Salary and Benefits		0
Expense/Equipment/Travel/Supplies/Other		0
Consultants/Contracted Services/Study		0
<b>Operational Costs: Other</b>		
Salary and Benefits		0
Expense/Equipment/Travel/Supplies/Other		0
Consultants/Contracted Services/Study	Payment to community-based treatment providers for provision of clinical screening, medical assessments/lab work, and extended-release injectable naltrexone (Vivitrol) injections for individuals with alcohol and/or opioid use disorders that are court-involved or at-risk for court involvement.	500,000
<b>Fixed Capital Construction/Major Renovation:</b>		
Construction/Renovation/Land/Planning Engineering		0
<b>Total State Funds Requested (must equal total from question #6)</b>		<b>500,000</b>

### 14. Program Performance

a. What specific purpose or goal will be achieved by the funds requested?



# The Florida Senate

## Local Funding Initiative Request

### Fiscal Year 2023-2024

LFIR # 1274

In response to the opioid epidemic and the increasing problem of alcohol abuse/dependence among Florida's citizens, the program facilitates recovery from substance use disorders, lower rates of opioid overdose, and reduced costs to society for employment issues, high-cost healthcare utilization, and court involvement related to alcohol and opioid use disorders.

**b. What activities and services will be provided to meet the intended purpose of these funds?**

Program funds substance abuse clinical screening, medical assessments/lab work, and extended-release injectable naltrexone (Vivitrol) medication to help individuals with opioid and/or alcohol use disorders achieve recovery through enhanced retention/completion rates for outpatient, residential, and other forms of psychosocial treatment.

**c. What direct services will be provided to citizens by the appropriation project?**

Clinical screening to diagnose alcohol and/or opioid use disorders; medical assessments/lab work to determine fitness of patients to receive medication and continue with maintenance protocols; and, medication administration for dosing extended-release injectable naltrexone every 3 to 4 weeks until cessation of the medical protocol as determined by the physician.

**d. Who is the target population served by this project? How many individuals are expected to be served?**

The requested funds, in conjunction with other state funds enable the program to serve 1,056 patients who are court-involved or at-risk for court involvement and present with alcohol and/or opioid use disorders. The requested funds would support clinical screening, medical assessments/lab work, and extended-release injectable naltrexone (Vivitrol) medication.

**e. What is the expected benefit or outcome of this project? What is the methodology by which this outcome will be measured?**

The use of medication in substance abuse treatment supports improved retention in traditional treatment. At least 60% of individuals receiving extended-release injectable naltrexone services will successfully complete or remain actively engaged in psychosocial treatment for alcohol and/or opioid use disorders at time of discharge from medication-assisted treatment (MAT) services. Algorithm includes all individuals successfully completing or still actively engaged in psychosocial treatment at time of discharge from services divided by all individuals discharged from MAT services.

**f. What are the suggested penalties that the contracting agency may consider in addition to its standard penalties for failing to meet deliverables or performance measures provided for the contract?**

The program has operated well throughout its 8-year history - current penalties in the contract for failure to meet deliverables or performance measures are sufficient.

**15. Requester Contact Information**

a. First Name  Last Name   
b. Organization   
c. E-mail Address   
d. Phone Number  Ext.

**16. Recipient Contact Information**

a. Organization   
b. Municipality and County

**c. Organization Type**

☐ For Profit Entity

☒ Non Profit 501(c)(3)



# The Florida Senate

## Local Funding Initiative Request

### Fiscal Year 2023-2024

LFIR # 1274

- ☐ Non Profit 501(c)(4)
- ☐ Local Entity
- ☐ University or College
- ☐ Other (please specify)

**d. First Name**  **Last Name**

**e. E-mail Address**

**f. Phone Number**

#### 17. Lobbyist Contact Information

**a. Name**

**b. Firm Name**

**c. E-mail Address**

**d. Phone Number**